2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Biological Processes, Apoptosis, Immune Mechanism, Microbiome, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

1807 Fixed-duration rituximab plus zanubrutinib as frontline therapy for previously untreated follicular and marginal zone lymphomas: Interim analysis of a multicenter phase II study

Ghada Araji, MD, Richard Corona2, Junmin Whiting, PHD3, Emilie Fussell4, Marian Araji5, Sabrina Hasan6, Celeste Bello, MD7, Lindsay Gardner8, Leidy Isenalumhe, MD, MS9, Supreet Kaur, MD10, Samuel Benjamin Reynolds, MD11, Lubomir Sokol, MD, PhD12, Yumeng Zhang, MD13, Bijal Shah, MD, MS14, Javier Pinilla-Ibarz, MD PhD15, Sameh Gaballa, MD16
1 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
2 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
3 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
4 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
5 Poznan University of Medical Sciences, Poznan, Poland
6 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
7 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
8 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
9 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
10 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
11 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
12 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
13 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
14 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
15 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
16 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Background: Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are the most common indolent B-cell non-Hodgkin lymphomas. Frontline rituximab monotherapy gives suboptimal disease control, while chemoimmunotherapy carries meaningful toxicity, leaving an unmet need for chemotherapy-free regimens. Bruton tyrosine kinase (BTK) signaling drives malignant B-cell survival in both histologies, and zanubrutinib, a next-generation BTK inhibitor, is active and well tolerated in relapsed/refractory MZL and FL. Unlike ibrutinib, it spares ITK and preserves rituximab-mediated ADCC. BTK inhibitors are not approved frontline in either histology. We report a preplanned interim analysis of fixed-duration rituximab plus zanubrutinib in treatment-naive FL and MZL.

Methods: In this ongoing, investigator-initiated, open-label phase II study (NCT06350318), adults with previously untreated MZL (cohort A) or grade 1–3A FL (cohort B) requiring systemic therapy received rituximab 375 mg/m2 on days 1, 8, 15, and 22 of cycle 1 and day 1 of cycles 2–6 (28-day cycles), plus zanubrutinib 320 mg once daily from cycle 1 day 1 for up to 24 cycles or until progression or intolerance. The primary endpoint was overall response rate (ORR) after 6 cycles by Lugano criteria. Each cohort follows a Simon two-stage design. Secondary endpoints included complete response (CR), progression-free survival (PFS), overall survival (OS), and safety (CTCAE v5.0). Patients completing ≥6 cycles were evaluable. Rates and 95% CIs used the Wilson method.

Results: At data cutoff, 27 patients were enrolled (MZL, 10; FL, 17). Median age was 67 years (range, 28–80), 37.0% were ≥70 years, ECOG PS was 0 in 74.1%, stage was III-IV in 77.8%. Among FL patients, 23.5% had grade 3A histology, 52.9% high-risk FLIPI, and 70.6% bulky disease by GELF criteria. MZL subtypes were nodal (40%), extra-nodal (30%), and splenic (30%).

At a median follow-up of 11.9 months (range, 0.7–26.3), 24 patients (MZL, n=9; FL, n=15) had completed the protocol-defined response assessment. ORR was 95.8% (23/24; 95% CI, 79.8–99.3), with CR in 7 (29.2%) and partial response (PR) in 16 (66.7%); 1 patient (4.2%) had progressive disease at the primary assessment. In MZL, ORR was 88.9% (8/9; 95% CI, 56.5–98.0), with CR and PR in 44.4% each; in FL, ORR was 100% (15/15; 95% CI, 79.6–100), with CR in 20.0% and PR in 80.0%. Both cohorts met the prespecified Simon first-stage efficacy thresholds (MZL, 6/7; FL, 9/9). Median time to first response was 2.8 months; 21 of the 23 responders (91.3%) achieved their first response at the first on-treatment assessment. Two patients (7.4%), one per cohort, progressed. Estimated 1-year PFS was 88.8% (95% CI, 62.1–97.1) overall, 87.5% in MZL and 90.0% in FL; median PFS was not reached. No deaths occurred (1-year OS 100%). Median zanubrutinib exposure was 10 cycles (range, 2–22); 81.5% completed all 6 rituximab cycles and 85.2% remain on treatment. 

Treatment-related adverse events (TRAEs) were predominantly grade 1–2, most commonly fatigue and skin rash (25.9% each), nausea (18.5%), ALT elevation (14.8%), diarrhea, chills, arthralgia, and AST elevation (11.1% each), and hypertension (3.7%). Grade ≥3 TRAEs occurred in 1 patient (3.7%), who experienced grade 4 neutropenia (the only grade 4 event observed) and grade 3 musculoskeletal pain. No grade ≥3 TRAEs occurred in the MZL cohort. No atrial fibrillation, major hemorrhage, or second malignancy occurred; all bleeding was grade 1. Grade ≥3 non-treatment-related infections occurred in 2 patients. Serious AEs (all requiring hospitalization) occurred in 3 patients (11.1%); 1 (3.7%) discontinued for treatment-related rash, 1 (3.7%) had a dose reduction, and 10 (37.0%) had a temporary interruption, most often for infection (n=4) or infusion-related reactions (n=3).

Conclusion: In this interim analysis, fixed-duration rituximab plus zanubrutinib produced a high response rate (ORR 95.8%; CR 29.2%) in previously untreated FL and MZL, and both cohorts met their first-stage efficacy boundaries. Early disease control was encouraging (1-year PFS 88.8%; no deaths), and the regimen demonstrated a manageable safety profile, with grade ≥3 treatment-related toxicity occurring in only 1 patient and no atrial fibrillation or major bleeding events. Longer follow-up, completion of accrual, and pending analyses of MRD kinetics are needed to further define the depth and durability of response with this 2-year fixed-duration strategy.

Ghada Araji, MD: No relevant conflicts of interest to declare.